NCT05020873View on ClinicalTrials.gov

Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and India

TerminatedOBSERVATIONAL
Enrollment

44

Participants

Timeline

Start Date

November 4, 2021

Primary Completion Date

August 31, 2023

Study Completion Date

August 31, 2023

Conditions
Sickle Cell Disease
Interventions
OTHER

Crizanlizumab

Prospective observational study. There is no treatment allocation. Patients administered crizanlizumab, that have started before inclusion of the patient into the study will be enrolled.

Trial Locations (5)

305

Novartis Investigative Site, Doha

20525

Novartis Investigative Site, Manama

32263

Novartis Investigative Site, Dammam

52700

Novartis Investigative Site, Al Ahmadi

82943

Novartis Investigative Site, Jizan

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY